<DOC>
	<DOCNO>NCT00152828</DOCNO>
	<brief_summary>This phase I/II study evaluate safety toxicity celecoxib combination standard concurrent cisplatin radiotherapy woman locally advanced cervix cancer . In addition , aim determine effect celecoxib ( Celebrex ) tumour oxygenation , interstitial fluid pressure , COX-2 level , prostaglandin E2 level , angiogenesis apoptosis .</brief_summary>
	<brief_title>Celebrex - Cervix : Celecoxib Treatment Patients With Locally Advanced Carcinoma Cervix</brief_title>
	<detailed_description />
	<mesh_term>Uterine Cervical Neoplasms</mesh_term>
	<mesh_term>Celecoxib</mesh_term>
	<mesh_term>Cyclooxygenase 2 Inhibitors</mesh_term>
	<criteria>Biopsyproven carcinoma cervix , visible/palpable tumour ; FIGO stage T1B3B , NO/1 , MO , treat definitive radiotherapy chemotherapy ECOG performance status 0 , 1 , 2 Adequate hematologic function ; Granulocyte count great 1.5 x 109/L , Platelet count great 100 x 109/L Adequate organ function ; Serum creatinine £ 1.25 x ULN , calculate creatinine clearance ³ 50 mL/min , Serum bilirubin £ 1.25 x ULN AST/ALT £ 3xULN No prior treatment cervix cancer Informed consent Use NSAID 2 week prior study enrollment Patients active malignancy another site Patients significant cardiac , renal , pulmonary disease medical condition may preclude radical therapy Patients significant history ischaemic heart disease stroke would deem suitable cessation daily prophylactic aspirin Patients history peptic ulcer disease previous NSAID related gastrointestinal bleeding Patients hypersensitivity NSAIDS celecoxib , sulfonamides Patients unwilling unable give inform consent</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2016</verification_date>
</DOC>